VEGFA and hepatocellular carcinoma: Recent Phase 3 trials have shown the benefit of combining PD-1 or PD-L1 antibodies with anti-VEGF reagent, bevacizumab, or anti-VEGFR agent, axitinib, resulting in FDA approval for the combinations across multiple tumor types including in an ICI-experienced setting (NCT02684006, lung; NCT03434379, hepatocellular carcinoma; and NCT02366143, kidney).